Kornimate/medical-research-clean huggingface dataset:
eosinophilic airway inflammation and mepolizumab

Conditions: Asthma

Summary: a drug (mepolizumab) that reduces allergic inflammation will affect the function of allergy cells called eosinophils which are produced by the body in response to allergen exposure.


Eligibility criteria:
inclusion criteria: * males or females age 18 to 50 yrs, * history of asthma based upon presence of asthma symptoms such as cough, shortness of breath, wheeze or chest tightness, * positive skin-prick test to a house dust mite extract, * forced expiratory volume at one second \>70% predicted pre-albuterol, \> 80% predicted post albuterol * \>12% increase in forced expiratory volume at one second following inhaled albuterol (180 µg) and/or * airway responsiveness to methacholine (pc20 \<8mg/ml). * \> 20% immediate drop in fev1 following inhaled antigen challenge. * safety laboratory assessments within normal ranges (labs to include complete blood count with differential, blood urea nitrogen, creatinine, aspartate aminotransferase, alanine aminotransferase, prothrombin time, partial thromboplastin time, and platelet count) * female subjects of child-bearing potential must have a negative urine pregnancy test (urine hcg) within 48 hours of the methacholine challenge at visit 2 and agree to use a reliable method of birth control for the duration of the study (reliable methods of birth control can include abstinence, barrier methods, oral contraceptives, injection contraceptives or skin absorption contraceptives). * in the opinion of the investigator, capable and willing to grant written informed consent and cooperate with study procedures and requirements. exclusion criteria: * use of inhaled or systemic corticosteroids or leukotriene inhibitors within 1 month of screening. * treatment with omalizumab (anti-ige) within 9 months of screening visit * concomitant use of any other monoclonal antibody * respiratory infection within 4 weeks of study * unstable asthma as indicated by self-report of increased symptoms or increased beta-agonist use over the previous 2 weeks. * female subjects who are pregnant, nursing or have a pregnancy planned during the course of study * current smokers (defined as smoked within the last year) or a former smoker with a history of \>5 pack years. * major health problems such as heart disease, type i and ii diabetes or lung diseases other than asthma. decisions regarding this criteria will be based upon the judgment of the investigator. * previous malignancy. * medication other than for asthma, allergies or contraception and that the investigator feels may interfere with the conduct of study (e.g. monoamine oxidase inhibitors and b-adrenergic antagonists in any form) * known history of allergic reaction to previous antibody administration. * prior treatment with an anti-interleukin-5 monoclonal antibody, * use of an investigational drug within 30 days of entering the study, * history of noncompliance with medical regimens or subjects who are considered unreliable.

Keywords: asthma allergic inflammation interleukin-5
paroxysmal positional vertigo & repositioning maneuvers

Conditions: Benign Paroxysmal Positional Vertigo

Summary: : benign paroxysmal positional vertigo is a condition related to vestibular system accompanied by dizziness, tinnitus and balance problems leading to increased fall risk and potential disability. various treatment options are available including pharmacotherapy and vestibular rehabilitation with varied results

objective: the objective of this study was to compare the efficacy of modified epley \& semont's maneuver with and without betahistine for bppv material \& methods: the study was a single blind randomized control trail. total number of patients were 97 as calculated by epitool calculator. duration of the study was of one year from 2 january 2021 to 1st january 2022. out of a total 97 patients, 90 met the inclusion criteria. these participants were randomized by lottery method into two equal groups. group a (control group) was receiving both maneuvers only while group b (experimental group) included participants receiving betahistine along with both maneuvers. the impact of dizziness and quality of life was measured through eq-5d-5l questionnaire and dizziness handicap inventory (dhi) in order to analyze the effectiveness of treatments. pre and post treatment results were compared within group by wilcoxon rank test and for between groups, mann whitney u test was performed

Eligibility criteria:
inclusion criteria: * age between 18-60 * positive modified dix hil pike test * repetitive vertigo spells affecting activities of daily livings (adls) exclusion criteria: * any cervical spine problem * vertigo due to central disease * tumors * systemic disease * cardiac disease * parkinson disease * bed bound patients

Keywords: bppv
interaction effects of vitamin d supplementation and aerobic exercises on balance and physical performance in children with down syndrome

Conditions: Children With Down Syndrome

Summary: objective: to investigate the interaction effects of vitamin d supplementation and aerobic exercises on balance control and physical performance in children with down syndrome (ds). methods: forty-five children with ds ranging in age from 8 to 12 years will be selected and will participate in this study. they will be assigned randomly using sealed envelopes into three equal groups (a, b and c). group a will consist of 15 children and will receive the conventional physical therapy program (cptp) only. group b will consist of 15 children and will receive the cptp plus the aerobic exercises. group c also will consist of 15 children and will receive the cptp, the aerobic exercises and vitamin d supplementation in the form of an oral dose of vitamin d3 1000 iu (cholecalciferol). the program of treatment will be 3 days/week for 12 weeks. evaluation of balance by using the biodex balance system and physical performance by using the six-minute walk test (6mwt) will be conducted at baseline and after 12 weeks of the treatment program.


Eligibility criteria:
inclusion criteria: * children with ds who can stand and walk independently * children with 25 (oh) vitamin d levels of 16 ng/ml or less * children who are not consuming estrogens, steroids or other medications that could interfere with vitamin d metabolism * the absence of visual and hearing impairments that could interfere with testing and training protocols * children with mild intellectual disabilities and were capable of understanding visual and verbal instructions. exclusion criteria: * medical conditions that will severely limit a child's participation in the study as cardiac problems. * musculoskeletal deformities of the lower limbs.

Keywords: aerobic exercises balance down syndrome physical performance vitamin d
study on the pharmacokinetics (pk) of dfn-15 vs comparator and food-effect on dfn-15 pk in healthy adult subjects

Conditions: Migraine

Summary: an open-label, three-way randomized, single dose crossover study comparing bioavailability of dfn-15 under fasting conditions versus comparator under fed conditions and to determine food-effect of dfn-15 in healthy adult subjects


Eligibility criteria:
inclusion criteria: * healthy, adult, male or female 19-55 years of age, inclusive, at screening. * medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ecgs, as deemed by the pi or designee. * females of childbearing potential: must either be sexually inactive (abstinent) for 30 days prior to the first dose and throughout the study or be using birth control method; female subjects of non-childbearing potential and must have undergone sterilization procedures or be postmenopausal for at least 1 year prior * male subject must agree to use contraception or abstain during the study until 90 days beyond the last dose of study drug. * understands the study procedures in the informed consent form (icf), and willing and able to comply with the protocol. exclusion criteria: * history or presence of hypersensitivity or idiosyncratic reaction to celecoxib, sulfonamides, aspirin or other nsaids or related compounds * history or presence of clinically significant medical or psychiatric condition or disease * history of any illness that, in the opinion of the pi or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study * liver enzyme tests greater than the upper limit of normal at screening * estimated creatinine clearance \<90 ml/minute at screening * history or presence of alcoholism * history or presence of bilateral pedal edema or generalized edema or fluid retention * female subjects who are pregnant or lactating or actively trying to conceive * positive urine drug or alcohol results at screening or check-in * positive cotinine at screening * positive results at screening for human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag), or hepatitis c virus (hcv) * seated blood pressure is less than 90/60 mmhg or greater than 140/90 mmhg at screening * seated heart rate is lower than 45 bpm or higher than 100 bpm at screening * has been on a diet incompatible with the on-study diet * unable to refrain from or anticipates the use of prohibited medications * donation of blood or significant blood loss within 56 days prior to the first dose of study drug; plasma donation within 7 days prior to the first dose of study drug * participation in another clinical trial within 28 days prior to the first dose of study drug
personalized medicine in patients with infective endocarditis

Conditions: Infective Endocarditis; Response, Acute Phase; Treatment

Summary: the hypothesis underlying this work is the identification of different sub phenotypes of patients with infective endocarditis through the study of the host's response to infection. furthemore, metagenomic sequencing may be a helpful supplement to ie diagnostic, especially when conventional tests fail to yield a diagnosis.

infective endocarditis is a life-threatening infection of heart valves and adjacent structures characterized by vegetations on valves and other endocardial surfaces, with tissue destruction and risk of embolization. the clinical variability, including the heterogeneous response to infection and the different antibiotic treatments make the identification of the underlying pathogens of infective endocarditis (ie) is critical for precision therapy. virulence factors mediate tissue adherence, host infiltration, immune resistance/evasion, and dynamic stress responses and confer enhanced pathogen survival, proliferation, and host invasion in animal models of infective endocarditis. to identify the microorganism and simultaneously considered the response of the host to the infection could improve the management of the infective endocarditis.

Eligibility criteria:
inclusion criteria: * diagnosis of active infective endocarditis according to the modified duke criteria. exclusion criteria: * pregnancy
sup-er protocol rct

Conditions: Birth Related Brachial Plexus Injury; Obstetrical Brachial Plexus Palsy

Summary: this study evaluates the ability of a supination and external rotation protocol to improve the arm function and anatomy of children with birth related brachial plexus injuries.

the brachial plexus is a group of 5 nerves from the spinal cord that provide the movement and sensation of an upper extremity. in some difficult deliveries, traction on the shoulder may lead to damage to the brachial plexus and will result in an arm that is paralyzed. this is called 'birth related brachial plexus injury' (brbpi). this may occur in up to 1/1000 births and the nerves may be injured minimally to severely. about 2/3 of children with this injury will recover to quite functional levels simply by maintaining looseness of joints while their nerves slowly heal. some children have nerve injuries severe enough that they require surgical reconstruction with nerve grafts and nerve transfers to achieve even adequate function. even in children with otherwise "good" recovery, the motions of external rotation of the shoulder and supination of the forearm are weaker, later to recover, and often incomplete. more importantly, lack of full motion leads to long term changes in the structure, growth, and posture of the shoulder requiring further musculoskeletal surgery, or a child with permanent deformity or disability. any gains in active and passive range of motion during the first year of life may improve these long-term shoulder outcomes. the investigators have instituted a program of early passive repositioning mostly using a custom sup-er (supination and external rotation) splint during early growth and development to improve arm position and range of motion where er and sup are weak. in compliant patients in a pilot study, the speed and strength of recovery of er and supination are improved compared to historical controls. it is a novel splint and protocol designed by the investigators. this study is a randomized controlled trial to evaluate the use of the sup-er protocol in multiple centres over a two year period by assessing the arm function at common time points in recovery. the subjects are randomized to the sup-er protocol or the currently accepted standard treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of brachial plexus injury at birth. * significant deficit in external rotation and/or supination of the affected limb based on clinical assessment using the toronto active movement scale at 6 weeks of age (external rotation ≤ 2 and/or supination ≤ 2) * tightness in passive range of motion of external rotation: any angle of less than 180°. * age 6-8 weeks exclusion criteria: * neuromuscular disorder * unwillingness or inability to comply with the requirements of the study protocol.

Keywords: birth related brachial plexus injury brachial plexus splint
effect of the coughing technique during subcutaneous heparin injection

Conditions: Thyroidectomy; Colon Surgery; Cholecystectomy; Inguinal Hernia

Summary: objective: to examine the effect of the medium intensity coughing technique during subcutaneous low molecular weight heparin injection on pain severity and individual satisfaction in general surgery patients. method: a prospective, quasi-experimental study included 100 patients who had prescribed a subcutaneous low molecular weight heparin injection once in 24 hours. each patient received two injections by the same researcher using standard injection technique with medium intensity coughing technique and only standard injection technique.

aims and objectives: the aim of this study was to examine the effect on the level of pain severity and satisfaction of patients of the medium intensity coughing technique applied to patients during the administration of subcutaneous low molecular weight heparin (lmwh) injection. design: this research was a prospective quasi-experimental study. methods: it was conducted with 100 patients in the general surgery clinic of a university hospital in the marmara region of turkey. subcutaneous lmwh injections were administered by the same nurse to the outer side of the right and left upper arms by the standard injection technique and the medium intensity coughing technique. immediately after the subcutaneous lmwh injection was given, a researcher who did not know which injection method had been used asked the patients to evaluate their pain levels by the visual analog scale (vas) and their satisfaction with the performance of the injection by the visual individual satisfaction scale (viss).

Eligibility criteria:
inclusion criteria: * participating voluntarily in the study * being over the age of 18, * having a doctor's prescription for subcutaneous low molecular weight heparin 0.6 ml treatment and not yet having begun treatment. * having no coagulation disorder, having no disorder that could affect pain perception, - * having no incision, lipodystrophy, or finding of infection at the injection site, * having no communication problem exclusion criteria: * not wanting to participate in the study, or during the course of the research, wishing to withdraw from the study * having any condition which would affect the sensation of pain * not being able to agree on a place or time * being less than 18 years of age

Keywords: subcutaneous heparin injection coughing technique pain individual satisfaction non-pharmacological method
strategies to improve prescribing in heart failure patients

Conditions: Chronic Heart Failure

Summary: the purpose of the study is to assess whether primary care physicians may uptitrate recommended drug therapies in stable heart failure patients if educational material and specialist support including phone or mail consultation are provided

heart failure is highly prevalent, particularly in elderly subjects, and costly, mainly because of the high rate of recurrent hospital admissions. although guideline-recommended treatments, such as beta-blockers and renin-angiotensin inhibitors, are effective on both mortality and morbidity, these drugs are very often underprescribed or used at lower doses than those shown to be beneficial in clinical trials, particularly in the primary care setting, for fear of adverse events. although referral to specialist services may improve prescription of recommended drugs and doses achieved, frequent consultations may be unfeasible and costly.the study is designed to assess whether active specialist support and educational material improve the prescription process for heart failure patients in primary care

Eligibility criteria:
inclusion criteria: * a confirmed diagnosis of heart failure wih depressed systolic function (left ventricular ejection fraction \<40% in the previous 6 months). * stable nyha class ii-iii * a clinical indication to implement drug therapy with betablockers and/or renin-angiotensin system inhibitors and current dose \<50% of the target dose exclusion criteria: * nyha class iv or clinically unstable * cardiac surgery or cardiac resynchronization therapy planned within the following 6 months * discharged to a rehabilitation unit refusal or impossibility to present to outpatient visits
apligraf versus standard therapy in the treatment of diabetic foot ulcers

Conditions: Diabetic Foot

Summary: the purpose of this study is to determine the ability of apligraf to improve the time to and incidence of complete wound closure of diabetic foot ulcers, as compared to diabetic foot ulcers treated with standard therapy.

ulceration of the diabetic foot is a result of multiple problems including repetitive stress on a neuropathic or insensate area that is often associated with an underlying bony prominence. by healing diabetic foot ulcers quickly the risks of infection, osteomyelitis (infeciton of the bone) and limb loss can be reduced. this study will evaluate the ability of apligraf to heal diabetic foot ulcers that have been present for at least 2 weeks and are between 1 - 16 cm2 in area. patients will be randomized to either (50:50 chance) treatment with apligraf or a saline moistened dressing regimen (standard therapy). all patients will receive standard cares for the ulcers which includes debridement, orthotics and off-loading throughout the treatment period.

Eligibility criteria:
inclusion criteria: * diabetic ulcer of primarily neuropathic origin on the plantar region of the forefoot * ulcer extending through the dermis but without sinus tract, tendon, capsule or bone exposure * ulcer present for at least 2 weeks and measuring 1- 16 cm2 * diminished sensesation on target extremity/foot * ulcer is not infected * type 1 or 2 diabetes with adequate glycemic control * adequate vascular supply to the target extremity exclusion criteria: * charcot foot * non-neuropathic ulcers * skin cancer within or adjacent to the target ulcer * osteomyelitis or an infected ulcer * clinically significant medical condition that would impair wound healing * females who are pregnant * received within 4 weeks of study entry systemic corticosteriods, immunosuppresive agents, radiation therapy or chemotherapy

Keywords: diabetic foot
a 6-month efficacy, safety, and tolerability study of rifaximin in preventing hepatic encephalopathy

Conditions: Hepatic Encephalopathy

Summary: the purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (he).


Eligibility criteria:
inclusion criteria: * must sign an informed consent form * in remission from past he * uses appropriate birth control measures * more than or equal to 18 years of age * must have potential to benefit from treatment * recent prior he episodes * capable and willing to comply with all study procedures * participant has personal support available * has a certain model end stage liver disease (meld) score * recent transjugular intrahepatic portosystemic shunt (tips) placement or revision exclusion criteria: * significant medical conditions, medical conditions that may impact study participation, or investigator decision not to include * allergies to the study drug or similar drugs * laboratory abnormalities * recent participation in another clinical trial * history of non-compliance * pregnant or at risk of pregnancy, or is lactating * recent alcohol consumption * active bacterial or viral infections * bowel issues * active malignancy * on a prohibited medication * liver transplant expected in near term * lactulose intolerance * participant shows presence of intestinal obstruction or has inflammatory bowel disease * ongoing or recent gi bleed